FDA Confirms PMA Support for BioCardia’s CardiAMP HF II Cell Therapy
BCDA•FDA minutes confirm that the ongoing CardiAMP HF II trial may support Premarket Approval for BioCardia’s CardiAMP Cell Therapy in ischemic heart failure with reduced ejection fraction. FDA has already deemed the system safe for CMS reimbursement and the therapy could address over one million US patients with HFrEF.
1. FDA Q-Sub Meeting Outcome
BioCardia received FDA minutes from its Q-Sub Meeting with CBER confirming that CardiAMP HF II trial data may satisfy requirements for a Premarket Approval application, the agency’s most rigorous pathway for high-risk devices. This marks a critical regulatory endorsement as the company seeks market clearance for its autologous cell therapy.
2. Significance of PMA Pathway
PMA is required to establish safety and effectiveness for high-risk medical devices before public use; FDA’s confirmation suggests the CardiAMP HF II trial could serve as one of two pivotal studies needed. Previously, FDA had indicated a preference for two well-designed trials in large indications like HFrEF.
3. Patient Population and Reimbursement
Ischemic HFrEF affects over one million patients in the US, highlighting significant market potential for a first-in-class cell therapy. FDA’s safety determination enables Centers for Medicare and Medicaid Services to reimburse investigational use in trial settings, reducing financial barriers to therapy adoption.
4. Next Steps and Upcoming Catalysts
BioCardia plans to publish its CardiAMP HF manuscript and pursue a PMDA submission in Japan by Q4 2026. The company will also continue enrollment in CardiAMP HF II and prepare its PMA filing based on full trial results.
